Fecal calprotectin one year after ileocaecal resection for Crohn's disease - A comparison with findings at ileocolonoscopy

Journal of Crohn's and Colitis

Volumn 8, Issue 8, 2014, Pages 789-795

  Lasson, Anders ^a   Strid, Hans ^b   Öhman, Lena ^b,c   Isaksson, Stefan ^b,c   Olsson, Mikael ^d   Rydström, Britt ^a   Ung, Kjell Arne ^e   Stotzer, Per Ove ^b  

^a Section of Rheumatology   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d Norra Alvsborg Hospital   (Sweden)

^e SKARABORG HOSPITAL   (Sweden)

Author keywords

Calprotectin; Crohn's disease; Fecal marker; Postoperative recurrence

Indexed keywords

CALGRANULIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; COLONOSCOPY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIARRHEA; FECES LEVEL; FEMALE; FOLLOW UP; HUMAN; ILEOCECAL RESECTION; ILEUM RESECTION; INFLAMMATORY INFILTRATE; INTESTINE ANASTOMOSIS; INTESTINE CRYPT; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; SMALL INTESTINE; ULCER; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FECES ANALYSIS; ILEOCAECAL RESECTION; ILEOCOLONOSCOPY; INTESTINE SURGERY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; CECUM; CHEMISTRY; FECES; ILEUM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CECUM; COLONOSCOPY; CROHN DISEASE; FECES; FEMALE; HUMANS; ILEUM; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; YOUNG ADULT;

EID: 84904515809     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.12.015     Document Type: Article

References (28)

1. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., Gendre J.P. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
2. Ramadas A.V., Gunesh S., Thomas G.A.O., Williams G.T., Hawthorne A.B. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010, 59:1200-1206.
3. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
4. Peyrin-Biroulet L., Oussalah A., Williet N., Pillot C., Bresler L., Bigard M.A. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011, 60:930-936.
5. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010, 105:289-297.
6. Rutgeerts P., Geboes K., Vantrappen G., Kerremans R., Coenegrachts J.L., Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984, 25:665-672.
7. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
8. Van Assche G., Dignass A., Reinisch W., van der Woude C.J., Sturm A., De Vos M., et al. The second european evidence-based consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010, 4:63-101.
9. Røseth A.G., Aadland E., Jahnsen J., Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997, 58:176-180.
10. Sipponen T., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008, 14:40-46.
11. Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M.K., Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119:15-22.
12. Lasson A., Simren M., Stotzer P.-O., Isaksson S., Öhman L., Strid H. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis 2013, 19:576-581.
13. D'Haens G., Ferrante M., Vermeire S., Baert F., Noman M., Moortgat L., et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2218-2224.
14. Moum B., Jahnsen J., Bernklev T. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 2010, 16:1091-1092.
15. Orlando A., Modesto I., Castiglione F., Scala L., Scimeca D., Rispo A., et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci 2006, 10:17-22.
16. Scarpa M., D'Incà R., Basso D., Ruffolo C., Polese L., Bertin E., et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum 2007, 50:861-869.
17. Lamb C.A., Mohiuddin M.K., Gicquel J., Neely D., Bergin F.G., Hanson J.M., et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009, 96:663-674.
18. Sorrentino D., Paviotti A., Terrosu G., Avellini C., Geraci M., Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010, 8:591-599. [e591].
19. Yamamoto T., Shiraki M., Bamba T., Umegae S., Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: a prospective pilot study. U Eur Gastroenterol J 2013, 1,5:368-374.
20. Naismith G.D., Smith L.A., Barry S.J.E., Munro J.I., Laird S., Rankin K., et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther 2013, 37:613-621.
21. Røseth A.G., Schmidt P.N., Fagerhol M.K. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999, 34:50-54.
22. Sandborn W.J., Feagan B.G., Hanauer S.B., Lochs H., Löfberg R., Modigliani R., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
23. Domenech E., Manosa M., Bernal I., Garcia-Planella E., Cabre E., Pinol M., et al. Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm Bowel Dis 2008, 14:508-513.
24. Kusano M., Ino K., Yamada T., Kawamura O., Toki M., Ohwada T., et al. Interobserver and intraobserver variation in endoscopic assessment of GERD using the 'Los Angeles' classification. Gastrointest Endosc 1999, 49:700-704.
25. Asfeldt A.M., Straume B., Paulssen E.J. Impact of observer variability on the usefulness of endoscopic images for the documentation of upper gastrointestinal endoscopy. Scand J Gastroenterol 2007, 42:1106-1112.
26. Smedh K., Olaison G., Jönsson K.A., Johansson K.E., Skullman S., Hallböök O. Interobserver variation of colonoileoscopic findings in Crohn's disease. Scand J Gastroenterol 1995, 30:81-86.
27. Summerton C.B., Longlands M.G., Wiener K., Shreeve D.R. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002, 14:841-845.
28. Dolwani S., Metzner M., Wassell J.J., Yong A., Hawthorne A.B. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004, 20:615-621.